Aaron Farberg, MD: Use of JAK Inhibitors for Alopecia Areata Treatment

January 13, 2026

Dr. Farberg explores the evolving treatment landscape for alopecia areata, with a focus on JAK inhibitors and their role in selectively targeting immune pathways involved in autoimmune hair loss. This discussion highlights how these therapies are changing expectations for disease control and long-term management.

Topics Covered:

The immune mechanisms behind alopecia areata
How JAK inhibitors work to interrupt inflammatory signaling
Benefits and considerations of selective immune targeting
What emerging data means for patient outcomes and quality of life

Explore Related Resources:

JAK Inhibitors for Psoriasis

Treatment Gaps for Patients with Alopecia Areata

MORE EXPERT PERSPECTIVES IN ALOPECIA AREATA:

Ted Lain, MD, MBA: Reviewing Results of the THRIVE-AA1 Trial in Severe Alopecia Areata

Ted Lain, MD, MBA, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, discusses the randomized phase 3 THRIVE-AA1 trial (NCT04518995), which assessed the safety

Amy McMichael, MD: Use of Deuruxolitinib for Hair Regrowth in Patients With Alopecia Areata

Amy McMichael, MD, discusses deuruxolitinib for patients with alopecia areata as an alternative to longer-term treatment options.

Paradi Mirmirani, MD: Addressing Treatment Gaps for Patients with Alopecia Areata

Dr. Mirmirani examines the current treatment landscape for extensive and severe alopecia areata, focusing on longstanding unmet needs and how recent FDA-approved therapies are beginning

Arash Mostaghimi, MD, MPH, FAAD: Assessing the Safety and Efficacy of Deuruxolitinib in Patients with Alopecia Areata

Dr. Mostaghimi reviews pivotal data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 clinical trials, which evaluated the safety and efficacy of deuruxolitinib in patients with

JCAD Archives